INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 86 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.24 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $233 | -22.6% | 7,381 | 0.0% | 0.01% | -13.3% |
| Q2 2023 | $301 | +2.4% | 7,381 | -6.3% | 0.02% | +15.4% |
| Q1 2023 | $294 | +7.3% | 7,881 | +0.3% | 0.01% | 0.0% |
| Q4 2022 | $274 | -99.9% | 7,859 | -0.2% | 0.01% | -38.1% |
| Q3 2022 | $441,000 | +8.1% | 7,872 | -0.3% | 0.02% | +16.7% |
| Q2 2022 | $408,000 | -28.9% | 7,894 | 0.0% | 0.02% | -21.7% |
| Q1 2022 | $574,000 | -38.5% | 7,894 | -0.1% | 0.02% | -20.7% |
| Q4 2021 | $933,000 | -17.4% | 7,898 | -6.1% | 0.03% | -19.4% |
| Q3 2021 | $1,129,000 | +88.8% | 8,412 | +127.7% | 0.04% | +80.0% |
| Q2 2021 | $598,000 | +564.4% | 3,694 | -42.4% | 0.02% | +900.0% |
| Q1 2017 | $90,000 | -24.4% | 6,412 | -29.4% | 0.00% | -33.3% |
| Q4 2016 | $119,000 | -25.2% | 9,077 | -2.9% | 0.00% | -40.0% |
| Q3 2016 | $159,000 | – | 9,344 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |